ROCO
1788
Market cap179mUSD
Jul 09, Last price
129.50TWD
1D
0.00%
1Q
-5.13%
Jan 2017
42.83%
IPO
192.59%
Name
Hi-Clearance Inc
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in 1989 and headquartered in New Taipei City, Taiwan, Hi-Clearance Inc. is a prominent supplier of medical devices and associated services throughout Taiwan. The company's comprehensive product range addresses various healthcare sectors, including renal care, cardiac health, radiation therapy, dentistry, oral surgery, and metabolic conditions. Its medical offerings encompass vital equipment such as dialyzers, dialysis machines, and reverse osmosis (RO) systems, complemented by essential consumables and pharmaceutical products. Hi-Clearance also provides specialized devices for interventional cardiology, radiology, and vascular surgery. For the dental field, it supplies consumables, implant materials, and equipment. Furthermore, the company offers blood glucose monitors, along with their related consumables and nutritional products. Beyond product provision, Hi-Clearance Inc. delivers extensive hemodialysis management services and specializes in the development and operation of dialysis centers. Diversifying its business, the company also engages in the distribution and servicing of healthy and natural beverages, and acts as an OEM provider for beverage raw materials and concentrates.
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||